NYSEAMERICAN:OGEN - Oragenics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.9293 +0.04 (+4.50 %) (As of 11/18/2018 04:51 AM ET)Previous Close$0.9293Today's Range$0.90 - $1.0252-Week Range$0.38 - $4.70Volume2.19 million shsAverage Volume2.49 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida. Receive OGEN News and Ratings via Email Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:OGEN Previous Symbol CUSIPN/A Webwww.oragenics.com Phone+1-813-2867900 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees6 Outstanding Shares11,840,000Market Cap$0.00 OptionableNot Optionable Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions What is Oragenics' stock symbol? Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN." When did Oragenics' stock split? How did Oragenics' stock split work? Shares of Oragenics reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split. How were Oragenics' earnings last quarter? Oragenics Inc (NYSEAMERICAN:OGEN) issued its quarterly earnings results on Tuesday, November, 13th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.13. View Oragenics' Earnings History. When is Oragenics' next earnings date? Oragenics is scheduled to release their next quarterly earnings announcement on Friday, February 15th 2019. View Earnings Estimates for Oragenics. Has Oragenics been receiving favorable news coverage? News headlines about OGEN stock have trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oragenics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. Are investors shorting Oragenics? Oragenics saw a decrease in short interest in October. As of October 31st, there was short interest totalling 1,314,544 shares, a decrease of 32.2% from the October 15th total of 1,938,732 shares. Based on an average trading volume of 3,754,165 shares, the days-to-cover ratio is presently 0.4 days. Currently, 9.1% of the shares of the company are short sold. View Oragenics' Current Options Chain. Who are some of Oragenics' key competitors? Some companies that are related to Oragenics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are Oragenics' key executives? Oragenics' management team includes the folowing people: Dr. Alan F. Joslyn, Pres, CEO & Director (Age 59)Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 62)Dr. Martin Handfield, Sr. VP of Discovery Research (Age 47)Dr. Guojun Nie Ph.D., Director of Process Devel.Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant How do I buy shares of Oragenics? Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Oragenics' stock price today? One share of OGEN stock can currently be purchased for approximately $0.9293. What is Oragenics' official website? The official website for Oragenics is http://www.oragenics.com. How can I contact Oragenics? Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900. MarketBeat Community Rating for Oragenics (NYSEAMERICAN OGEN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 58 (Vote Outperform)Underperform Votes: 59 (Vote Underperform)Total Votes: 117MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: Hedge Funds - Risk or Reward?